Journal of Clinical Oncology
Articles in this Issue
Systemic cytokine dynamics during neoadjuvant chemotherapy versus endocrine therapy and CDK4/6 inhibition in high-risk luminal breast cancer: Results from the GEICAM/2019-01-CARABELA trial.
619 Background: Chemotherapy (CT) and CDK4/6 inhibitors modulate antitumor immunity primarily within the tumor microenviro...
Impact of the COVID-19 pandemic on early-stage breast cancer post-lumpectomy breast radiation therapy completion.
e12682 Background: Whole-breast radiation therapy (RT) following lumpectomy has become a standard of care for early-stage...
Zongertinib combined with T-DXd in HER2-positive metastatic gastric, gastroesophageal junction, or esophageal carcinoma (mGEAC): First results from a phase Ib/II dose-escalation trial.
3106 Background: Zongertinib, an irreversible TKI, selectively inhibits HER2 while sparing wild-type EGFR, thereby minimiz...
Association of incidence and severity of neurotoxicity with six FDA-approved chimeric receptor T-cell therapies: A meta-analysis of 61 studies including 8,376 patients.
e23351 Background: Immune effector cell-associated neurotoxicity syndrome (ICANS) is a significant and serious side effect...
Association of baseline clinical factors and treatment-related variables with survival in phase I solid tumor trials.
11039 Background: Phase I trials in solid oncology increasingly use biomarker-based enrollment and evaluate diverse therap...
Intracellular pharmacology and trafficking to support sequential activation of SynchroLINK T2X antibody-drug conjugates in cancer.
e15045 Background: Clinical performance of antibody–drug conjugates (ADCs) is often constrained by rapid payload release,...
Stereotactic body radiotherapy versus non-SBRT radiotherapy for medically inoperable stage I non–small cell lung cancer in elderly patients: A systematic review and meta-analysis.
e20038 Background: Elderly patients with medically inoperable stage I non–small cell lung cancer (NSCLC) are commonly trea...
Enhanced detection of clinically actionable non-V600 <i>BRAF</i> alterations by DNA+RNA amplicon-based sequencing in a real-world solid tumor cohort.
e15086 Background: Although BRAF V600 mutations are established therapeutic targets, growing evidence suggests that non-V6...
CDC analysis of pancreatic cancer and diabetes-associated pancreatic cancer mortality among older adults (1999-2020).
e16447 Background: Pancreatic cancer is a major cause of cancer related mortality in the United States. New-onset diabetes...
Tumor miRNA expression as a potential biomarker of immune-related toxicity in patients with melanoma or urothelial carcinoma treated with immune checkpoint inhibitors.
e14588 Background: Immune checkpoint inhibitors (ICIs) have substantially improved clinical outcomes in several solid tumo...
RAPID: A pilot feasibility study of rapid dinutuximab infusion in patients with relapsed/refractory (RR) high-risk neuroblastoma (HRNBL).
10013 Background: Dinutuximab is a key component of therapy for HRNBL and is widely used in the RR setting. Standard admin...
Non-surgical management and outcome of 1,113 patients with stage I-II non-small cell lung cancer (NSCLC) in a 20-year cohort.
8045 Background: Surgical resection is the primary therapy for stage I-II NSCLC but not performed in a subset of patients...
Trends in historical response rates: A meta-analysis of KRAS G12C inhibitors in pretreated metastatic pancreatic cancer—Effects on ORR and disease control.
e16443 Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with KRAS mutation...
OrigAMI-5: A randomized, phase 3 study of amivantamab plus pembrolizumab and carboplatin vs standard of care pembrolizumab plus platinum and 5-fluorouracil as first-line treatment in recurrent/metastatic head and neck cancer.
TPS6127 Background: Recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC) is associated with signific...
Epidemiology of melanoma in Syria: A retrospective analysis from the national cancer center.
e21524 Background: Epidemiological data on melanoma from conflict-affected regions like Syria are critically scarce, hinde...
Placing oncology and conflicts of interest in a global context: Evidence from the large international ONCOTRUST-2 study.
9042 Background: Conflicts of interest (COIs) arising from relationships between pharmaceutical industry and oncologists c...
Inpatient chemotherapy and immunotherapy encounters in the United States: Recent trends, acute complications, and palliative care utilization.
e23144 Background: Most chemotherapy and immunotherapy treatments are administered in the ambulatory setting, while inpati...
Landscape of therapeutically actionable HRR gene variants in Moroccan breast and ovarian cancer: A systematic review and meta-analysis.
e15075 Background: Hereditary breast and ovarian cancers (HBOC) in Morocco remain underexplored, despite a steady increase...
Cadonilimab or ivonescimab plus axitinib in metastatic mucosal melanoma: Results from a phase Ib trial.
9516 Background: Mucosal melanoma (MM) is a rare and aggressive cancer with a poor prognosis. Unlike its more common count...
Development and implementation of a pilot prescreening tool for potential clinical trial participants for an immune checkpoint inhibitor trial.
e13655 Background: Clinical trial accrual can be challenging in a community-based cancer setting. During limited appointme...
Reducing manual chart review in oncology: Validation of an AI-based monitoring tool for lung cancer staging and biomarker tracking.
e13662 Background: Continuous monitoring of evolving staging and molecular data is essential for clinical decision support...
Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: A prospective clinical trial.
4103 Background: Neoadjuvant immunochemotherapy has emerged as a promising strategy for locally advanced gastric and gastr...
Incidence of cardiac lymphoma, mesothelioma, and sarcoma: A population-based study of primary malignant cardiac tumors.
e24000 Background: Primary malignant cardiac tumors (PMCTs) are considered extremely rare neoplasms, with limited...
Compassionate release for incarcerated patients with cancer: A nationwide policy review.
e24040 Background: Cancer is the leading cause of death among incarcerated individuals in the United States, who experienc...
Role of oxidative stress and neutrophil reprogramming in mediating venous thrombosis in colorectal cancer.
e15733 Background: Colorectal cancer associated venous thrombosis (CRC-VT) is a major cause of mortality in CRC patients,...